latest news releases from the newsroom
Security Intelligence Technologies, Inc.
Security Intelligence Technologies, Inc. Signs New Distribution Agreement Valued at $800,000 and Receives First Order for $100,000
NEW YORK, Jan. 25, 2006 (PRIMEZONE) -- Security Intelligence Technologies, Inc.(OTCBB:SITG) and its subsidiary, Homeland Security Strategies, Inc. (HSS) announced today that it recently signed a distribution agreement with a prominent Far Eastern marketing company, appointing them as licensee with the right to sell its counterterrorism, surveillance, counter-surveillance and security products in their country.
Interland Announces Earnings Release Date and Conference Call
ATLANTA, Jan. 25, 2006 (PRIMEZONE) -- Interland (Nasdaq:INLD), soon to be Web.com, Inc, a leading provider of websites and online services for small and medium-sized businesses (SMBs), today announced that it will report results for its transition period ending December 31, 2005, before market on February 9, 2006.
FCI USA, Inc.
Photo Release -- FCI USA, Inc. Announces New Apex 150 Sealed Connectors, USCAR Compliant and Built for Demanding Environments
NOVI, Mich., Jan. 25, 2006 (PRIMEZONE) -- FCI USA, Inc., a leading supplier of electrical connectors to the OEM automotive industry, now offers a new USCAR compliant APEX 150 family of smaller sealed electrical connectors for especially demanding environments, including engine compartment and safety critical applications, announced Ed de Chazal, FCI marketing manager.
AlphaRx Receives Notice of Allowance for U.S. Patent on Its Drug Delivery Platform
MARKHAM, Ontario, Jan. 25, 2006 (PRIMEZONE) -- AlphaRx Inc. (OTCBB:ALRX), an emerging biopharmaceutical company utilizing proprietary drug delivery technology to develop novel formulations of drugs, has received a Notice of Allowance from the United States Patent and Trademark Office for its patent application entitled "Vehicle For Topical Delivery of Anti-Inflammatory Compounds." The platform is an integral part of the Company's lead product Indaflex(tm), which is undergoing a Phase II clinical trial.